Clinigen Expands U.S. Presence With Opening Of New Yardley Headquarters
Local Government Officials and the British Government help open new office
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’) the global pharmaceutical and services company, officially opened its new US headquarters last night at a reception attended by members of local government, leading pharmaceutical and biotech companies and the US Director of the British Government’s international commercial arm, UK Trade & Investment (“UKTI”).
The office in Yardley, PA combines the Group’s existing operations in Philadelphia, PA and Princeton, NJ following Clinigen’s acquisition of Idis in April 2015, providing a dedicated base for the Group’s 30-strong integrated and expanding US team of patient access experts.
The office will accommodate employees from Clinigen’s Clinical Trial Services (CTS) division, the global market leader in the management and supply of medicines for clinical trials, and Idis Managed Access (MA), the leading provider of early access programs for innovative new medicines. These teams have relocated from the Philadelphia and Princeton sites respectively.
The move to Yardley is part of Clinigen’s ongoing strategy to strengthen its US presence and enables further expansion as the business continues to grow. It also follows Clinigen’s strategic alliance, agreed last year, with Nashville-based Cumberland Pharmaceuticals to provide complementary support in the development, marketing, promotion and distribution of the Group’s products in the US.
Clinigen marked the opening of the office with a reception on Wednesday 18 May 2016 attended by leading pharmaceutical companies, patient organizations and government officials, with special guests from the UK Trade & Investment.
Martin Cook, Deputy Consul General New York and Director of UKTI USA
“It has been fantastic to work alongside the Clinigen team to help facilitate the consolidation of the Group’s operations in the US as they complete the integration of their business. We are very pleased to see such an innovative, rapidly growing and unique UK company expanding and attracting the industry’s best talent in what is such an important market. We wish Clinigen every success.”
John B. Lewis, Vice Chair, Board of Supervisors, Lower Makefield Township, PA
“Pennsylvania has become a hub for cutting edge pharmaceutical and biotechnology companies and I would like to personally welcome Clinigen to the area. We are encouraged to see international market-leading life science organisations like Clinigen opting to locate its facilities in Yardley; especially a company so focused on providing patients with access to the often life-saving, medicines they need.”
Steve Glass, Group Managing Director, Clinigen Group said:
“Yardley’s close proximity to both New York and Philadelphia and its location in an area of specialist pharmaceutical expertise made it an ideal location for our fully integrated US services team. One year on from our acquisition of Idis we now have a better, stronger, market leading business ideally positioned to provide the right medicine to the right patient at the right time in the important US market and across the world.”
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’) the global pharmaceutical and services company, officially opened its new US headquarters last night at a reception attended by members of local government, leading pharmaceutical and biotech companies and the US Director of the British Government’s international commercial arm, UK Trade & Investment (“UKTI”).
The office in Yardley, PA combines the Group’s existing operations in Philadelphia, PA and Princeton, NJ following Clinigen’s acquisition of Idis in April 2015, providing a dedicated base for the Group’s 30-strong integrated and expanding US team of patient access experts.
The office will accommodate employees from Clinigen’s Clinical Trial Services (CTS) division, the global market leader in the management and supply of medicines for clinical trials, and Idis Managed Access (MA), the leading provider of early access programs for innovative new medicines. These teams have relocated from the Philadelphia and Princeton sites respectively.
The move to Yardley is part of Clinigen’s ongoing strategy to strengthen its US presence and enables further expansion as the business continues to grow. It also follows Clinigen’s strategic alliance, agreed last year, with Nashville-based Cumberland Pharmaceuticals to provide complementary support in the development, marketing, promotion and distribution of the Group’s products in the US.
Clinigen marked the opening of the office with a reception on Wednesday 18 May 2016 attended by leading pharmaceutical companies, patient organizations and government officials, with special guests from the UK Trade & Investment.
Martin Cook, Deputy Consul General New York and Director of UKTI USA
“It has been fantastic to work alongside the Clinigen team to help facilitate the consolidation of the Group’s operations in the US as they complete the integration of their business. We are very pleased to see such an innovative, rapidly growing and unique UK company expanding and attracting the industry’s best talent in what is such an important market. We wish Clinigen every success.”
John B. Lewis, Vice Chair, Board of Supervisors, Lower Makefield Township, PA
“Pennsylvania has become a hub for cutting edge pharmaceutical and biotechnology companies and I would like to personally welcome Clinigen to the area. We are encouraged to see international market-leading life science organisations like Clinigen opting to locate its facilities in Yardley; especially a company so focused on providing patients with access to the often life-saving, medicines they need.”
Steve Glass, Group Managing Director, Clinigen Group said:
“Yardley’s close proximity to both New York and Philadelphia and its location in an area of specialist pharmaceutical expertise made it an ideal location for our fully integrated US services team. One year on from our acquisition of Idis we now have a better, stronger, market leading business ideally positioned to provide the right medicine to the right patient at the right time in the important US market and across the world.”